Surfactant status and respiratory outcome in premature infants receiving late surfactant treatment

Pediatr Res. 2019 Feb;85(3):305-311. doi: 10.1038/s41390-018-0144-3. Epub 2018 Aug 15.

Abstract

Background: Many premature infants with respiratory failure are deficient in surfactant, but the relationship to occurrence of bronchopulmonary dysplasia (BPD) is uncertain.

Methods: Tracheal aspirates were collected from 209 treated and control infants enrolled at 7-14 days in the Trial of Late Surfactant. The content of phospholipid, surfactant protein B, and total protein were determined in large aggregate (active) surfactant.

Results: At 24 h, surfactant treatment transiently increased surfactant protein B content (70%, p < 0.01), but did not affect recovered airway surfactant or total protein/phospholipid. The level of recovered surfactant during dosing was directly associated with content of surfactant protein B (r = 0.50, p < 0.00001) and inversely related to total protein (r = 0.39, p < 0.0001). For all infants, occurrence of BPD was associated with lower levels of recovered large aggregate surfactant, higher protein content, and lower SP-B levels. Tracheal aspirates with lower amounts of recovered surfactant had an increased proportion of small vesicle (inactive) surfactant.

Conclusions: We conclude that many intubated premature infants are deficient in active surfactant, in part due to increased intra-alveolar metabolism, low SP-B content, and protein inhibition, and that the severity of this deficit is predictive of BPD. Late surfactant treatment at the frequency used did not provide a sustained increase in airway surfactant.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Birth Weight
  • Bronchopulmonary Dysplasia / prevention & control*
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases
  • Male
  • Phospholipids / metabolism
  • Pulmonary Surfactant-Associated Protein B / metabolism
  • Pulmonary Surfactants / administration & dosage*
  • Respiration / drug effects*

Substances

  • Phospholipids
  • Pulmonary Surfactant-Associated Protein B
  • Pulmonary Surfactants